As with other drugs, Skyrizi can cause side effects, such as headache and injection site reactions. Skyrizi can cause certain side effects, some of which are more common than others. These side ...
MedPage Today on MSN21h
FDA Expands Guselkumab Approval to Crohn's DiseaseThe FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
The randomised double-blind Phase III Astro trial (NCT05528510) study examined a subcutaneous injectable version ... and AbbVie’s Skyrizi (risankizumab). Both drugs brought in $132m and $11bn ...
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease ...
It can be administered in-office or by self-injection after training. Developed in partnership with Germany’s Boehringer Ingelheim, Skyrizi was approved in Japan and Canada in the past few weeks.
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback